Search Results

There are 2579 results for: content related to: Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

  1. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 465–471, G. T. Grossberg, J. T. Olin, M. Somogyi and X. Meng

    Version of Record online : 11 FEB 2011, DOI: 10.1111/j.1742-1241.2011.02641.x

  2. Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch

    The Journal of Clinical Pharmacology

    Volume 49, Issue 4, April 2009, Pages: 430–443, Dr Gilbert Lefèvre, Ms Monika Büche, Dr Greg Sedek, Mr Steve Maton, Dr Albert Enz, Dr Ulrike Lorch, Dr Cyriaque Sagan and Dr Silke Appel-Dingemanse

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008330161

  3. You have free access to this content
    Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 4, August 2010, Pages: 246–253, Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki and Teus Van Laar

    Version of Record online : 29 MAR 2010, DOI: 10.1111/j.1755-5949.2010.00141.x

  4. You have free access to this content
    Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

    International Journal of Clinical Practice

    Volume 69, Issue 5, May 2015, Pages: 518–530, G. Alva, J. L. Cummings, J. E. Galvin, X. Meng and D. M. Velting

    Version of Record online : 16 FEB 2015, DOI: 10.1111/ijcp.12621

  5. Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 1, January 2000, Pages: 1–12, Michael W. Jann

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.20.1.1.34664

  6. You have free access to this content
    Rivastigmine for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline S Birks, Lee Yee Chong and John Grimley Evans

    Published Online : 22 SEP 2015, DOI: 10.1002/14651858.CD001191.pub4

  7. Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 2, February 2008, Pages: 246–252, Dr Gilbert Lefèvre, Mrs Françoise Pommier, Dr Greg Sędek, Dr Mark Allison, Dr Hsun-Lun Aaron Huang, Mrs Beate Kiese, Dr Yu-Yun Ho and Dr Silke Appel-Dingemanse

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007312154

  8. You have free access to this content
    A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

    International Journal of Geriatric Psychiatry

    Volume 22, Issue 5, May 2007, Pages: 456–467, Bengt Winblad, Jeffrey Cummings, Niels Andreasen, George Grossberg, Marco Onofrj, Carl Sadowsky, Stefanie Zechner, Jennifer Nagel and Roger Lane

    Version of Record online : 22 MAR 2007, DOI: 10.1002/gps.1788

  9. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

    International Journal of Clinical Practice

    Volume 60, Issue 1, January 2006, Pages: 110–118, T. Dantoine, 1 S. Auriacombe, 2 M. Sarazin, 3 H. Becker, 4 J-J Pere and 5 I. Bourdeix 5

    Version of Record online : 20 DEC 2005, DOI: 10.1111/j.1368-5031.2005.00769.x

  10. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

    International Journal of Geriatric Psychiatry

    Volume 19, Issue 3, March 2004, Pages: 243–249, A. Burns, R. Spiegel and P. Quarg

    Version of Record online : 13 FEB 2004, DOI: 10.1002/gps.1058

  11. Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans

    The Journal of Clinical Pharmacology

    Volume 44, Issue 6, June 2004, Pages: 599–604, Dr. Lucy Lee, Dr. Mohammad Hossain, Dr. Yanfeng Wang and Dr. Greg Sedek

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004265645

  12. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 5, May 2007, Pages: 545–551, S. V. Frankfort, B. A. Appels, A. de Boer, L. R. Tulner, J. P. C. M. van Campen, C. H. W. Koks, J. H. Beijnen and B. A. Schmand

    Version of Record online : 16 NOV 2006, DOI: 10.1002/pds.1345

  13. Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application

    The Journal of Clinical Pharmacology

    Volume 47, Issue 4, April 2007, Pages: 471–478, Dr Gilbert Lefèvre, Dr Greg Sędek, Dr Hsun-Lun Aaron Huang, Dr Marc Saltzman, Dr Mitchell Rosenberg, Dr Beate Kiese and Dr Peter Fordham

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006297748

  14. Risk of Pneumonia in New Users of Cholinesterase Inhibitors for Dementia

    Journal of the American Geriatrics Society

    Volume 63, Issue 5, May 2015, Pages: 869–876, Edward Chia-Cheng Lai, Monera B. Wong, Isao Iwata, Yinghong Zhang, Cheng-Yang Hsieh, Yea-Huei Kao Yang and Soko Setoguchi

    Version of Record online : 27 APR 2015, DOI: 10.1111/jgs.13380

  15. Development of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma – Optimization of the limits of detection and quantitation

    ELECTROPHORESIS

    Volume 33, Issue 4, February 2012, Pages: 644–652, Irene N. Nicolaou and Constantina P. Kapnissi-Christodoulou

    Version of Record online : 27 MAR 2012, DOI: 10.1002/elps.201100286

  16. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry

    Biomedical Chromatography

    Volume 18, Issue 3, April 2004, Pages: 160–166, Albert Enz, Alain Chappuis and Andre Dattler

    Version of Record online : 11 DEC 2003, DOI: 10.1002/bmc.304

  17. You have free access to this content
    Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 6, December 2010, Pages: 330–336, Frederick A. Schmitt, Martin R. Farlow, Xiangyi Meng, Sibel Tekin and Jason T. Olin

    Version of Record online : 15 OCT 2010, DOI: 10.1111/j.1755-5949.2010.00182.x

  18. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

    International Journal of Geriatric Psychiatry

    Volume 15, Issue 3, March 2000, Pages: 242–247, George T. Grossberg, Hannes B. Stahelin, John C. Messina, Ravi Anand and Jeffrey Veach

    Version of Record online : 18 MAY 2000, DOI: 10.1002/(SICI)1099-1166(200003)15:3<242::AID-GPS110>3.0.CO;2-7

  19. Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease

    The Journal of Clinical Pharmacology

    Volume 41, Issue 10, October 2001, Pages: 1082–1090, Dr. J.V.S. Gobburu, Dr. V Tammara, Dr. L Lesko, Dr. S. S. Jhee, Dr. J. J. Sramek, Dr. N. R. Cutler and Dr. Ruihua Yuan

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700122012689

  20. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study

    Movement Disorders

    Volume 30, Issue 7, June 2015, Pages: 912–918, Eugenia Mamikonyan, Sharon X. Xie, Emilie Melvin and Daniel Weintraub

    Version of Record online : 25 APR 2015, DOI: 10.1002/mds.26236